Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)

• Autores: McMurray, John J. V.; Anand, Inder S.; Diaz, Rafael; Maggioni, Aldo P.; O'Connor, Christopher; Pfeffer, Marc A.; Solomon, Scott D.; Tendera, Micha; van Veldhuisen, Dirk J.; Moetaz, Albizem; Cheng, Sunfa; Scarlata, Debra; Swedberg, Karl; Young, James B.; Toblli, Jorge Eduardo; RED-HF Committees Investigators
• Año de publicación: 2013
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: Heart Failure; Anaemia
• Institución: Consejo Nacional de Investigaciones Científicas y Técnicas

AIMS: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes. METHODS AND RESULTS: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate < 60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106-117) g/L. CONCLUSION: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.
Fil: McMurray, John J. V.. University of Glasgow; Reino Unido
Fil: Anand, Inder S.. University of Minnesota; Estados Unidos
Fil: Diaz, Rafael. Estudios Clínicos Latinoamérica; Argentina
Fil: Maggioni, Aldo P.. Associazione Nazionale Medici Cardiologi Ospedalieri; Italia
Fil: O'Connor, Christopher. University of Duke; Estados Unidos
Fil: Pfeffer, Marc A.. Brigham and Women’s Hospita; Estados Unidos
Fil: Solomon, Scott D.. Brigham and Women’s Hospital; Estados Unidos
Fil: Tendera, Micha. Medical University of Silesia; Polonia
Fil: van Veldhuisen, Dirk J.. University of Groningen; Países Bajos
Fil: Moetaz, Albizem. Amgen Inc.; Estados Unidos
Fil: Cheng, Sunfa. Amgen Inc.; Estados Unidos
Fil: Scarlata, Debra. Amgen Inc.; Estados Unidos
Fil: Swedberg, Karl. University of Gothenburg; Suecia
Fil: Young, James B.. Cleveland Clinic. Endocrinology and Metabolism Institute; Estados Unidos
Fil: Toblli, Jorge Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: RED-HF Committees Investigators. No especifíca;